Home / Why AGADA? / How we work
How we work
We shape our support around the needs of your program, providing focused scientific expertise where it can make the greatest impact.
How we work
Built to integrate with your ecosystem
We bring an agile, collaborative and responsive approach to every engagement, shaping our support around the needs of your program rather than a rigid process. Whether you engage us at a single stage or across multiple points in development, we work to de-risk programs, protect data integrity and help your teams progress with confidence.
1.
Refined for your program:
We shape our approach around the needs of each program, not the other way around.
2.
Direct access to senior experts:
Our lean model keeps scientific expertise close to the work and communication clear.
3.
Built to de-risk progress:
We help reduce avoidable risk through rigorous science and practical support.
4.
Protecting data integrity:
Our work is designed to support reliable outputs and maintain trust in the data.
Shipping and logistics
AGADA Biosciences manages complex global logistics to deliver borderless support for your rare disease program. We coordinate bidirectional shipping to deliver biopsy-readiness kits to your global trial sites and to securely transport frozen tissue samples back to our facility. Our team applies active temperature monitoring, dry-ice top-ups and strict chain-of-custody protocols to ensure your samples remain viable and your clinical data is protected.
Our services
We provide rigorous efficacy studies, fit-for-purpose bioassays and precision tissue handling to accelerate your rare disease program from early discovery through clinical execution.
Clinical specimen management
Protecting longitudinal data integrity with strict procedural control for frozen muscle biopsies.
Bioanalytical method validation
Pre-validated methods and fit-for-purpose bioassays designed to accurately measure critical biomarkers and accelerate rare disease drug development.
Preclinical services
Rigorous efficacy studies and established in vivo models designed to de-risk your rare disease program before human trials.
Translational strategy consulting
Successful rare disease programs begin with the right strategy. AGADA’s senior scientific team provides expert translational and regulatory guidance to help you define study objectives, select meaningful biomarker endpoints, and generate evidence that supports confident decision-making. By aligning your program with FDA and EMA expectations from the outset, we help reduce risk and accelerate development.
Get in touch
To learn how AGADA Biosciences could support your program, get in touch with our team and start the conversation.
Our onboarding process
We operate with low red tape to establish fast escalation paths and predictable schedules. Our senior scientists are involved early to define the exact context of use and keep your clinical readouts interpretable before laboratory work begins.
1.
Introductory scoping:
You speak directly with our senior scientific leadership to discuss services, establish study design requirements and define the precise context of use.
2.
Rapid protocol alignment:
We execute a confidentiality agreement and collaborate on study design to generate specific instructions and quotes without demanding multiple layers of unnecessary internal approvals.
3.
Deployment and execution:
We finalize the scope of work and activate our teams, bringing clinical biopsy sites up to speed in as little as two to three months to keep your rare disease program on track.
Meet the leadership team
